Holen Sie sich die Stockscreener-App
8.49
3.52%
-0.31
Handel nachbörslich:
8.35
-0.14
-1.65%
Evommune Inc Aktie (EVMN) Neueste Nachrichten
Evommune (EVMN) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress - biospace.com
Evommune Reports Phase 2a EVO301 Atopic Dermatitis Data at EADV 2026 via 8-K Filing - Kalkine Media
Evommune to present phase 2a atopic dermatitis data at EADV By Investing.com - Investing.com Nigeria
Evommune (EVMN) Edges Higher: Shares Gain 1.59% to $9.60 as Buyers Hold SupportCup and Handle - siam.in
Evommune: Pipeline Reset After EVO756 Failure, All Eyes On EVO301 (NYSE:EVMN) - Seeking Alpha
Analysts Have Conflicting Sentiments on These NA Companies: Evommune, Inc. (EVMN) and Douglas AG (OtherDOUDF) - The Globe and Mail
Cantor Fitzgerald reiterates Evommune stock rating at Overweight - Investing.com
Evommune (EVMN) Drops EVO756 for Eczema. Can EVO301 Carry the Pipeline? - finance.yahoo.com
EVMN: Advancing novel therapies in atopic dermatitis and migraine, with strong funding and pipeline momentum - TradingView
Evommune Releases Updated Corporate Presentation Compliant with Regulation FD - Kalkine Media
Form 8K Evommune Inc For: 15 September By Investing.com - Investing.com India
Evommune posts updated corporate presentation outlining pipeline progress, cash runway and 2027–2028 milestones - TradingView
Evommune（NYSE: EVMN）が現金を賢明に活用することを期待しています。 - Moomoo
Analysts Offer Insights on NA Companies: Chime Financial, Inc. Class A (CHYM), ServiceTitan, Inc. Class A (TTAN) and Evommune, Inc. (EVMN) - The Globe and Mail
Analysts Offer Insights on NA Companies: Evommune, Inc. (EVMN), Inhibrx Biosciences Inc (INBX) and Circle Internet Group, Inc. Class A (CRCL) - The Globe and Mail
Evommune stock maintains Buy rating despite trial setback By Investing.com - Investing.com Nigeria
RBC cuts Evommune stock price target on drug trial setback By Investing.com - Investing.com Australia
Evommune Scraps Itch Drug After Second Phase 2 Failure, Stock Slides 18% - finance.biggo.com
EVMN Maintains Rating by Leerink Partners -- Price Target Lowered to $22 - GuruFocus
Evommune Drops AD Program Following Phase 2B Trial Failure - The Dermatology Digest
Why this company's stock took a hit just 10 months after its IPO - The Business Journals
Evommune’s EVO-756 fails dermatitis study; focus on migraine - BioWorld News
Stifel reiterates Evommune stock rating after phase 2b trial miss By Investing.com - Investing.com Nigeria
Stifel reiterates Evommune stock rating after phase 2b trial miss - Investing.com
Evommune Reports EVO756 Phase 2b Trial Failure in Atopic Dermatitis, Halts Development for This Indication - Kalkine Media
Evommune (NYSE:EVMN) Price Target Lowered to $21.00 at Royal Bank Of Canada - MarketBeat
RBC cuts Evommune stock price target on drug trial setback - Investing.com India
Why is Evommune stock plunging today? By Investing.com - Investing.com Australia
Evommune's (EVMN) Neutral Rating Reaffirmed at HC Wainwright - MarketBeat
Evommune stock maintains Buy rating despite trial setback - Investing.com
Evommune Halts Atopic Dermatitis Program Following Trial Failure - Benzinga
Why is Evommune stock sliding 13% today? - Investing.com
RBC Cuts Price Target on Evommune to $21 From $29, Keeps Outperform, Speculative Risk - marketscreener.com
Why is Evommune stock sliding 13% today? By Investing.com - Investing.com Canada
Why is Evommune stock tumbling today? By Investing.com - Investing.com Canada
Evommune's EVO756 suffers second Phase IIb setback in two months with AD miss - AllSci
Evommune’s EVO756 fails phase 2b trial in atopic dermatitis By Investing.com - Investing.com India
Evommune stock tumbles after trial misses primary endpoint By Investing.com - Investing.com South Africa
Evommune stock tumbles after trial misses primary endpoint - investing.com
Why Is EVMN Stock Down 13% After-Hours? - Yahoo Finance
Evommune scraps eczema drug after trial miss, shares plunge - Reuters
Evommune’s EVO756 fails phase 2b trial in atopic dermatitis - investing.com
Why is Evommune stock plunging today? - investing.com
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):